NASDAQ:ADMA - ADMA Biologics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.53 -0.05 (-0.90 %) (As of 10/21/2018 04:56 AM ET)Previous Close$5.53Today's Range$5.40 - $5.624252-Week Range$2.01 - $6.96Volume305,314 shsAverage Volume238,030 shsMarket Capitalization$258.63 millionP/E Ratio-2.90Dividend YieldN/ABeta2.35 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency. It distributes its products through independent distributors, sales agents, specialty pharmacies, and others. The ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey. Receive ADMA News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:ADMA CUSIPN/A Webwww.admabiologics.com Phone201-478-5552 Debt Debt-to-Equity Ratio0.79 Current Ratio10.65 Quick Ratio8.88 Price-To-Earnings Trailing P/E Ratio-2.90 Forward P/E Ratio-4.13 P/E GrowthN/A Sales & Book Value Annual Sales$22.76 million Price / Sales11.26 Cash FlowN/A Price / CashN/A Book Value$0.89 per share Price / Book6.21 Profitability EPS (Most Recent Fiscal Year)($1.91) Net Income$-43,750,000.00 Net Margins-119.34% Return on Equity-89.78% Return on Assets-29.51% Miscellaneous Employees295 Outstanding Shares46,350,000Market Cap$258.63 million ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions What is ADMA Biologics' stock symbol? ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA." How were ADMA Biologics' earnings last quarter? ADMA Biologics Inc (NASDAQ:ADMA) issued its quarterly earnings data on Friday, August, 10th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by $0.03. The biotechnology company had revenue of $4.66 million for the quarter, compared to the consensus estimate of $5.35 million. ADMA Biologics had a negative net margin of 119.34% and a negative return on equity of 89.78%. View ADMA Biologics' Earnings History. When is ADMA Biologics' next earnings date? ADMA Biologics is scheduled to release their next quarterly earnings announcement on Friday, November 2nd 2018. View Earnings Estimates for ADMA Biologics. What price target have analysts set for ADMA? 5 brokerages have issued twelve-month target prices for ADMA Biologics' shares. Their predictions range from $7.50 to $13.00. On average, they anticipate ADMA Biologics' share price to reach $10.50 in the next twelve months. This suggests a possible upside of 89.9% from the stock's current price. View Analyst Price Targets for ADMA Biologics. What is the consensus analysts' recommendation for ADMA Biologics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ADMA Biologics. Who are some of ADMA Biologics' key competitors? Some companies that are related to ADMA Biologics include Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Coherus Biosciences (CHRS), BAVARIAN NORDIC/S (BVNRY), BioCryst Pharmaceuticals (BCRX), Heska (HSKA), Novavax (NVAX), Fate Therapeutics (FATE), Avrobio (AVRO), Mesoblast (MESO), Vericel (VCEL), Voyager Therapeutics (VYGR), Scholar Rock (SRRK), NanoString Technologies (NSTG) and Gritstone Oncology (GRTS). Who are ADMA Biologics' key executives? ADMA Biologics' management team includes the folowing people: Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 41)Dr. Jerrold B. Grossman D.P.S., Co-Founder & Vice Chairman (Age 70)Mr. Brian Lenz, VP & CFO (Age 46)Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 72)Mr. James Hauert, Sr. VP of Commercialization & Strategy How do I buy shares of ADMA Biologics? Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ADMA Biologics' stock price today? One share of ADMA stock can currently be purchased for approximately $5.53. How big of a company is ADMA Biologics? ADMA Biologics has a market capitalization of $258.63 million and generates $22.76 million in revenue each year. The biotechnology company earns $-43,750,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. ADMA Biologics employs 295 workers across the globe. What is ADMA Biologics' official website? The official website for ADMA Biologics is http://www.admabiologics.com. How can I contact ADMA Biologics? ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected] MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 234 (Vote Outperform)Underperform Votes: 137 (Vote Underperform)Total Votes: 371MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe ADMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/21/2018 by MarketBeat.com StaffFeatured Article: What is the 52-week high/low?